Increased potency of vanadium using organic ligands
The in vivo glucose lowering effect of orally administered inorganic vanadium compounds in diabetes was first reported in our laboratory in 1985. While both vanadate and vanadyl forms of vanadium are orally active, they are still not well absorbed. We have synthesized several organic vanadium compounds and one compound, bis(maltolato)oxovanadium(IV) or BMOV, has been extensively investigated. BMOV proved effective in lowering plasma glucose and lipids in STZ-diabetic rats when administered in drinking water over a 25 week period. The maintenance dose (0.18 mmol/kg/day) was approximately 50% of that required for vanadyl sulfate (VS). Secondary complications of diabetes were prevented by BMOV and no marked toxicity was noted. Oral gavage of STZ-diabetic rats with BMOV also reduced blood glucose levels. The ED50 for BMOV was 0.5 mmol/kg, while for VS the estimated ED50 was 0.9 mmol/kg. BMOV was also effective by the intraperitoneal route in STZ-diabetic rats. The ED50 was 0.08 mmol/kg compared to 0.22 mmol/kg for VS. Some animals treated p.o. or i.p. remained euglycemic for up to 14 weeks. An i.v. infusion of BMOV of 0.05 mmol/kg over a 30 min period reduced plasma glucose levels by 50% while VS was not effective.
Key wordsVanadium diabetes insulin-mimetic hypertension
Unable to display preview. Download preview PDF.
- 1.Willsky GR: Vanadium in the biosphere. In: N. Dennis Chaasteen (ed.). Vanadium in biological systems. Kluwer Academic Publishers, Dordrecht, 1990, pp 124Google Scholar
- 8.Tamura S, Brown TA, Dubler RE, Larner J: Insulin-like effect of vanadate on adipocyte glycogen synthase and on phosphorylation of 95,000 dalton subunit of insulin receptor. Biochem Biophys Research Communication 113: 8042, 1983Google Scholar
- 16.Nakhooda AF, Like AA, Marliss EB: Diabetes mellitus in the ‘BB’ Wistar rat. In: E.J. Andrews, B.C. Ward and N.H. Altman (eds). Spontaneous Animal Models of Human Disease. Volume I, Academic Press, Toronto, 1979, pp 131–136Google Scholar
- 19.Battell ML, Yuen VG, McNeill JH: Treatment of BB rats with vanadyl sulfate. Pharmacological Communications 1 (4): 291–301, 1992Google Scholar
- 25.Roschin AV, Ordizhonidze EK, Shalganova IV: Vanadium-toxicity, metabolism, carrier state. Jour Hyg Epid Microbiol Immunol 24: 377–383, 1980Google Scholar
- 28.Cam MC, Faun J, McNeill JH: Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin diabetic rats. Metabolism 1994 (in press)Google Scholar
- 31.Rocchini AP: Is insulin resistance in hypertension a generalized phenomena? In: U. Smith, N.E. Bruun, T. Hedner and B. Hokfelt (eds). Hypertension is an insulin resistant disorder: genetic factors and cellular mechanisms. Excerpta Medica, 1992, pp 213–225Google Scholar
- 39.Underwood EJ: Vanadium In: Trace elements in human and animal nutrition. Academic Press, New York, 1977, pp 388–397Google Scholar
- 43.Dai S, Yuen VG, Orvig C, McNeill JH: Prevention of diabetes-induced pathology in STZ-diabetic rats by bis(maltolato)oxovanadium(JV). Pharmacological Communications 3 (4): 311–321, 1993Google Scholar